Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

grifols malaysia sdn. bhd. - human immunoglobulin proteins -

Stati Uniti - Ingliż - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 16 mg in 1 ml - aralast np is an alpha1 -proteinase inhibitor (alpha1 -pi) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe congenital deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). aralast np increases antigenic and functional (anti-neutrophil elastase capacity, anec) serum levels and antigenic lung epithelial lining fluid levels of alpha1 -pi. the effect of augmentation therapy with any alpha1 -pi, including aralast np, on pulmonary exacerbations and on the progression of emphysema in alpha1 -antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy with aralast np or aralast are not available. aralast np is not indicated as therapy for lung disease in patients in whom severe congenital alpha1 -pi deficiency has not been established. aralast np is contraindicated in immunoglobulin a (iga) deficient patients with antib

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human plasma protein >90% gamma globulin - solution for injection - 1.6g/10ml %w/v

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

csl behring gmbh - human anti-d immunoglobulin - solution for injection in pre-filled syringe - 300 microgram(s) - specific immunoglobulins; anti-d (rh) immunoglobulin

Stati Uniti - Ingliż - NLM (National Library of Medicine)

ethicon, inc - human thrombin (unii: 6k15abl77g) (human thrombin - unii:6k15abl77g) - human thrombin 2000 [iu] in 2 ml - evithrom® thrombin, topical (human), is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. evithrom® thrombin, topical (human), may be used in conjunction with an absorbable gelatin sponge, usp. - do not use in individuals known to have an anaphylactic or severe systemic reaction to evithrom® or to human blood products. - do not use for the treatment of severe or brisk arterial bleeding. risk summary there are no data with evithrom® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evithrom® . it is not known whether evithrom® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. evithrom® should be given to a pregnant woman only if clearly needed. in the u.s. general population, the estimated background

Stati Uniti - Ingliż - NLM (National Library of Medicine)

csl behring ag - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 6 g - carimune® nf is indicated for the maintenance treatment of patients with primary immunodeficiencies (pid), e.g., common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency.30,32-34 carimune® nf is preferable to intramuscular immune globulin (human) preparations in treating patients who require an immediate and large increase in the intravascular immunoglobulin level28 , in patients with limited muscle mass, and in patients with bleeding tendencies for whom intramuscular injections are contraindicated. the infusions must be repeated at regular intervals. please see dosage and administration section. a controlled study was performed in children in which carimune® was compared with steroids for the treatment of acute (defined as less than 6 months duration) itp. in this study sequential platelet levels of 30,000, 100,000, and 150,000/µl were all achieved faster with carimune® than with steroids and without any of the side effects associated with steroids.29,35 howeve